Fosfomycin: The Antibiotic Making a Comeback Against Resistant UTIs in Seniors
"A closer look at how fosfomycin is being used to combat tough-to-treat urinary tract infections in the elderly, and what the future holds for this old antibiotic."
Urinary tract infections (UTIs) are a common ailment, especially among older adults. What was once a straightforward condition to treat has become increasingly complex due to the rise of antibiotic-resistant bacteria. This is where fosfomycin, an older antibiotic, is making a comeback, offering a potential solution for these difficult-to-treat infections.
Fosfomycin is a cell-wall active antibiotic known for its bactericidal activity against a wide range of bacteria, both gram-positive and gram-negative. While it has been around for decades, its use has been revitalized as other antibiotics lose their effectiveness. A recent study has investigated the use of fosfomycin in treating ceftriaxone-resistant Enterobacteriaceae urinary tract infections in elderly patients, providing valuable insights into its efficacy and safety.
This article delves into the findings of this research, exploring how fosfomycin is being used in a 1400-bed teaching hospital to combat UTIs caused by resistant bacteria. We'll examine the effectiveness of fosfomycin, potential resistance issues, and what this means for the future of treating UTIs in the elderly.
Clinical Effectiveness Across UTI Types
Evidence summarized in the cited studies includes both uncomplicated and complicated urinary tract infections. One evaluation reported successful treatment of lower UTI in 92% of patients within the first week and 98% after one month. The FOSFOMIC study assessed the clinical and microbiological effectiveness and safety of intravenous fosfomycin for complicated UTIs caused by Escherichia coli, comparing it with other intravenous antimicrobials. Another study examined whether introducing fosfomycin into treatment regimens increased fosfomycin resistance.
First-Line Use With Important Limits
Oral fosfomycin is described as a guideline-recommended first-line treatment for uncomplicated cystitis. The cited clinical guidance also reports lower clinical and microbiological cure rates than some other antibiotics for this indication. Fosfomycin sensitivity may be based on Escherichia coli breakpoints, and Scottish guidance advises monitoring the clinical response and considering an alternative agent if symptoms persist. The FOSUTI study is examining whether oral fosfomycin can be non-inferior to standard care for children with UTIs, potentially supporting more home treatment with an infrequently dosed, low-cost, off-patent antibiotic.
From Established UTI Use to MDR Applications
Fosfomycin has been used for UTI prophylaxis and treatment because it is predominantly excreted in active form into urine and has greater activity in a low-pH environment. A review of oral fosfomycin use at a large UK hospital describes the drug as increasingly used against multidrug-resistant organisms causing UTIs. A separate review highlights oral fosfomycin-trometamol in the context of limited treatment options for male UTIs caused by multidrug-resistant Enterobacterales. These sources portray fosfomycin as an established urinary antibiotic whose role has expanded as resistance narrows alternatives.
Fosfomycin: A Powerful Tool Against Resistant UTIs
The study focused on patients with cystitis caused by ceftriaxone-resistant Enterobacteriaceae, a type of bacteria increasingly resistant to common antibiotics. These patients were given a 3g dose of fosfomycin trometamol (FT), an oral formulation of the drug. For complicated cystitis, patients sometimes received 3g of FT every other day for a total of three doses. The study tracked the outcomes of these patients, looking at both clinical and microbiological cures.
- High Clinical Success Rate: The study found that 71.3% of patients achieved clinical cure with fosfomycin, experiencing no reported adverse drug events.
- Microbiological Cure: Microbiological cure was documented in 60% of patients.
- Resistance Development: A significant concern was the development of resistance to fosfomycin in 30% of patients with recurrent UTIs within three months.
- Prior Antibiotic Use: In patients who previously received antibiotics, the clinical cure rate was 71.6%.
- Dosage Impact: Patients receiving a single dose of fosfomycin had a similar clinical cure rate (71.6%), but a higher percentage developed recurrent infections.
Comparative Evidence in Acute Uncomplicated UTI
A 2026 Lancet report identifies a systematic review and meta-analysis comparing fosfomycin trometamol with comparator antibiotics for acute uncomplicated urinary tract infections in women. A separate comparative clinical efficacy review describes comparisons with other common oral antibiotics using evidence from recent clinical trials and meta-analyses. Together, these sources indicate that current research is evaluating fosfomycin comparatively rather than considering it in isolation. The available source descriptions do not provide a single pooled result, so the relative effectiveness should be interpreted from the underlying review findings.
Why Treatment May Be Limited or Fail
One source reports that fosfomycin remains infrequently used despite effectiveness because of limited approvals, resistance concerns, and the availability of alternatives. Another treatment-failure guide identifies bacterial resistance mechanisms and incorrect use among reasons fosfomycin may not work for a UTI. These concerns mean that fosfomycin should not be treated as universally effective for every urinary infection. Persistent symptoms require clinical reassessment and consideration of alternative treatment options.
Balancing Convenience and Reliability
Fosfomycin may be attractive when infrequent oral dosing and activity against resistant organisms are important considerations. However, its suitability depends on the infection, local susceptibility information, and the patient's clinical response. Comparisons with other antibiotics should therefore weigh effectiveness and tolerability alongside resistance risk and the need for treatment escalation.
The Future of Fosfomycin and UTIs
The study's findings suggest that fosfomycin remains an effective antibiotic for treating UTIs, particularly those caused by resistant bacteria in older adults. However, the emergence of resistance is a significant concern that needs to be addressed. Strategies to minimize resistance development might include:
Testing Fosfomycin Against Meropenem
The FOREST study protocol describes an investigator-driven randomized controlled trial comparing fosfomycin with meropenem for bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. This design reflects the need to evaluate fosfomycin in serious resistant infections rather than relying only on uncomplicated cystitis data. Because the cited source is a study protocol, it establishes the planned comparison rather than reporting final effectiveness results. Its focus places fosfomycin within a broader effort to define alternatives for resistant bloodstream-associated urinary infections.
A Role in the AMR Era
A 2025 review describes fosfomycin as a valuable addition to the UTI treatment armamentarium, particularly as antimicrobial resistance rises. It identifies the drug's unique mechanism, broad-spectrum activity, and safety profile as reasons it may remain important for multidrug-resistant infections. The future role of fosfomycin will depend on how these advantages translate into clinical practice and resistance management. Its continued use is therefore presented as part of the response to multidrug-resistant infections rather than as a replacement for every existing therapy.
Resistance and Severe Infection Management
The cited Cureus article examines fosfomycin resistance in Escherichia coli, including its mechanisms, trends, and clinical challenges. It reports that intravenous fosfomycin is being used more frequently for severe systemic infections such as bacteremia, complex UTIs, and infections caused by carbapenem-resistant Enterobacterales. This shift reflects the difficulty of treating infections in which resistance limits conventional options. At the same time, rising use in these settings makes resistance monitoring important for preserving fosfomycin's usefulness.
Individualized Treatment Decisions
For patients, fosfomycin's practical value may depend on whether the infection is susceptible, whether symptoms improve, and whether oral treatment is appropriate. A clinician may need to reassess therapy when symptoms persist or when resistance is suspected. In older adults and other patients with complicated illness, the balance between convenience, effectiveness, and escalation to intravenous treatment can be especially important. These decisions are individualized rather than guaranteed by fosfomycin's reputation against resistant bacteria.
#NAME?
Fosfomycin offers a valuable tool in the fight against antibiotic-resistant UTIs, but its long-term effectiveness depends on careful management and responsible use. Further research is needed to optimize treatment strategies and minimize the development of resistance, ensuring that this older antibiotic remains a viable option for future generations.